• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.缺氧会增加非小细胞肺癌细胞对补体攻击的敏感性。
Cancer Immunol Immunother. 2009 Nov;58(11):1771-80. doi: 10.1007/s00262-009-0685-8. Epub 2009 Mar 4.
2
Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.人补体因子H的下调使非小细胞肺癌细胞对补体攻击敏感,并减少体内肿瘤生长。
J Immunol. 2007 May 1;178(9):5991-8. doi: 10.4049/jimmunol.178.9.5991.
3
Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.siRNA 抑制膜补体抑制剂表达(CD46、CD55、CD59)可使肿瘤细胞在体外对补体攻击敏感。
Curr Cancer Drug Targets. 2010 Dec;10(8):922-31. doi: 10.2174/156800910793357952.
4
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.补体抑制剂CD46、CD55和CD59在肿瘤细胞上的表达不能预测滤泡性非霍奇金淋巴瘤患者接受利妥昔单抗治疗后的临床结局。
Blood. 2001 Sep 1;98(5):1352-7. doi: 10.1182/blood.v98.5.1352.
5
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.癌症免疫治疗的障碍:肿瘤中膜补体调节蛋白(mCRP)的表达。
Mol Immunol. 2003 Sep;40(2-4):109-23. doi: 10.1016/s0161-5890(03)00112-3.
6
Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.人肺癌细胞系表达细胞膜补体抑制蛋白,对补体介导的细胞溶解具有极强的抗性;体外与人正常呼吸道上皮的比较及抗性机制的探究。
Clin Exp Immunol. 1998 Aug;113(2):173-82. doi: 10.1046/j.1365-2249.1998.00581.x.
7
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.非小细胞肺癌细胞产生一组功能性补体因子I及其可溶性辅因子。
Mol Immunol. 2008 Jan;45(1):169-79. doi: 10.1016/j.molimm.2007.04.025. Epub 2007 Jun 4.
8
The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.补体调节蛋白CD46和CD59,而非CD55,在人乳腺和结肠肿瘤组织的腺上皮中高表达。
APMIS. 1998 Sep;106(9):869-78. doi: 10.1111/j.1699-0463.1998.tb00233.x.
9
CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.CRISPR/Cas9技术构建的人CD46、CD55和CD59基因敲除细胞系作为补体研究工具
J Immunol Methods. 2018 May;456:15-22. doi: 10.1016/j.jim.2018.02.004. Epub 2018 Feb 12.
10
K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.K562红白血病细胞具备多种抵抗补体裂解的机制。
Int J Cancer. 2001 Sep;93(6):848-54. doi: 10.1002/ijc.1406.

引用本文的文献

1
UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment.未折叠蛋白反应诱导的细胞内C5aR1促进对缺氧肿瘤微环境的适应。
Cell Death Dis. 2025 Jul 22;16(1):547. doi: 10.1038/s41419-025-07862-z.
2
Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment.缺氧诱导的补体成分 3 促进脑胶质母细胞瘤微环境中的侵袭性肿瘤生长。
JCI Insight. 2024 Aug 22;9(19):e179854. doi: 10.1172/jci.insight.179854.
3
The Factor H protein family: The switchers of the complement alternative pathway.补体旁路途径的开关:因子 H 蛋白家族。
Immunol Rev. 2023 Jan;313(1):25-45. doi: 10.1111/imr.13166. Epub 2022 Nov 16.
4
Association of Complement-Related Proteins in Subjects With and Without Second Trimester Gestational Diabetes.伴或不伴中期妊娠糖尿病受试者中补体相关蛋白的相关性研究。
Front Endocrinol (Lausanne). 2021 Mar 30;12:641361. doi: 10.3389/fendo.2021.641361. eCollection 2021.
5
Complement in Tumourigenesis and the Response to Cancer Therapy.补体在肿瘤发生及癌症治疗反应中的作用
Cancers (Basel). 2021 Mar 10;13(6):1209. doi: 10.3390/cancers13061209.
6
Complement and Cancer-A Dysfunctional Relationship?补体与癌症——一种功能失调的关系?
Antibodies (Basel). 2020 Nov 5;9(4):61. doi: 10.3390/antib9040061.
7
Drivers and regulators of humoral innate immune responses to infection and cancer.体液固有免疫应答在感染和癌症中的驱动因素和调节因子。
Mol Immunol. 2020 May;121:99-110. doi: 10.1016/j.molimm.2020.03.005. Epub 2020 Mar 18.
8
Context-dependent roles of complement in cancer.补体在癌症中的语境相关作用。
Nat Rev Cancer. 2019 Dec;19(12):698-715. doi: 10.1038/s41568-019-0210-0. Epub 2019 Oct 30.
9
Complement in Metastasis: A Comp in the Camp.补体在转移中:营地中的伙伴。
Front Immunol. 2019 Apr 3;10:669. doi: 10.3389/fimmu.2019.00669. eCollection 2019.
10
Complement Activation as a Helping Hand for Inflammophilic Pathogens and Cancer.补体激活作为亲炎症病原体和癌症的助力之手。
Front Immunol. 2019 Jan 10;9:3125. doi: 10.3389/fimmu.2018.03125. eCollection 2018.

本文引用的文献

1
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.肿瘤细胞上补体抑制剂表达对保护性T细胞免疫的调节作用。
Cancer Res. 2008 Aug 15;68(16):6734-42. doi: 10.1158/0008-5472.CAN-08-0502.
2
Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression.碳水化合物抗原唾液酸化路易斯a——其在癌症进展中的病理生理意义及诱导机制
Chang Gung Med J. 2007 May-Jun;30(3):189-209.
3
Hypoxia: life on the edge.缺氧:边缘求生。
Antioxid Redox Signal. 2007 Sep;9(9):1303-7. doi: 10.1089/ars.2007.1730.
4
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.非小细胞肺癌细胞产生一组功能性补体因子I及其可溶性辅因子。
Mol Immunol. 2008 Jan;45(1):169-79. doi: 10.1016/j.molimm.2007.04.025. Epub 2007 Jun 4.
5
Vascular endothelial growth factor and its relationship to inflammatory mediators.血管内皮生长因子及其与炎症介质的关系。
Clin Cancer Res. 2007 May 15;13(10):2825-30. doi: 10.1158/1078-0432.CCR-06-2416.
6
Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.人补体因子H的下调使非小细胞肺癌细胞对补体攻击敏感,并减少体内肿瘤生长。
J Immunol. 2007 May 1;178(9):5991-8. doi: 10.4049/jimmunol.178.9.5991.
7
Worldwide trends in lung cancer pathology.全球肺癌病理学趋势。
Respirology. 2006 Sep;11(5):533-8. doi: 10.1111/j.1440-1843.2006.00909.x.
8
CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells.CD46在调节对凋亡细胞和坏死细胞的天然免疫识别中起关键作用。
J Biol Chem. 2005 Oct 28;280(43):36342-54. doi: 10.1074/jbc.M506579200. Epub 2005 Aug 8.
9
C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation.C4b结合蛋白与坏死细胞和DNA结合,限制DNA释放并抑制补体激活。
J Exp Med. 2005 Jun 20;201(12):1937-48. doi: 10.1084/jem.20050189.
10
Overview of monoclonal antibodies in cancer therapy: present and promise.癌症治疗中单克隆抗体概述:现状与前景
Crit Rev Oncol Hematol. 2005 Apr;54(1):11-29. doi: 10.1016/j.critrevonc.2004.10.011.

缺氧会增加非小细胞肺癌细胞对补体攻击的敏感性。

Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.

作者信息

Okroj Marcin, Corrales Leticia, Stokowska Anna, Pio Ruben, Blom Anna M

机构信息

Department of Laboratory Medicine, Section of Medical Protein Chemistry, University Hospital, UMAS, Lund University, entrance 46, 205 02 Malmö, Sweden.

出版信息

Cancer Immunol Immunother. 2009 Nov;58(11):1771-80. doi: 10.1007/s00262-009-0685-8. Epub 2009 Mar 4.

DOI:10.1007/s00262-009-0685-8
PMID:19259664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11030643/
Abstract

The complement system can be specifically targeted to tumor cells due to molecular changes on their surfaces that are recognized by complement directly or via naturally occurring antibodies. However, tumor cells often overexpress membrane-bound complement inhibitors protecting them from complement attack. We have previously shown that non-small cell lung cancer (NSCLC) cells, additionally to membrane-bound inhibitors, produce substantial amounts of soluble regulators such as factor I (FI) and factor H (FH). Since low oxygen concentration is associated with rapidly growing solid tumors, we studied how NSCLC cells protect themselves from complement attack under hypoxic conditions. Unexpectedly, mRNA levels and secretion of both FI and FH were significantly decreased already after 24 h exposure to hypoxia while cell viability measured by XTT assay and annexin V/7-AAD staining was affected only marginally. Furthermore, we observed decrease of mRNA level and loss of membrane-bound complement inhibitor CD46 and increased deposition of early (C3b) and terminal (C9) complement components on hypoxic NSCLC cells. All three complement pathways (classical, lectin and alternative) were employed to deposit C3b on cell surface. Taken together, our results imply that under hypoxic conditions NSCLC give up some of their available defense mechanisms and become more prone to complement attack.

摘要

由于肿瘤细胞表面的分子变化可被补体直接识别或通过天然存在的抗体识别,补体系统可特异性地作用于肿瘤细胞。然而,肿瘤细胞通常会过度表达膜结合补体抑制剂,从而保护自身免受补体攻击。我们之前已经表明,非小细胞肺癌(NSCLC)细胞除了膜结合抑制剂外,还会产生大量的可溶性调节因子,如I因子(FI)和H因子(FH)。由于低氧浓度与快速生长的实体瘤有关,我们研究了NSCLC细胞在缺氧条件下如何保护自己免受补体攻击。出乎意料的是,暴露于缺氧环境24小时后,FI和FH的mRNA水平和分泌量就显著下降,而通过XTT法和膜联蛋白V/7-氨基放线菌素D染色测定的细胞活力仅受到轻微影响。此外,我们观察到缺氧的NSCLC细胞上mRNA水平下降,膜结合补体抑制剂CD46丢失,早期(C3b)和终末(C9)补体成分的沉积增加。所有三种补体途径(经典途径、凝集素途径和替代途径)都被用于在细胞表面沉积C3b。综上所述,我们的结果表明,在缺氧条件下,NSCLC会放弃一些可用的防御机制,更容易受到补体攻击。